The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | The cardiotoxicity of full-length light chains in patients with cardiac AL amyloidosis
In this video, Panagiota-Efstathia Nikolaou, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the role of free light chains in patients with cardiac AL amyloidosis, and shares some insights into a study which compared the cardiotoxicity of full-length light chains in patients with cardiac AL amyloidosis versus other plasma cell dyscrasias. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
